Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P14854
UPID:
CX6B1_HUMAN
Alternative names:
Cytochrome c oxidase subunit VIb isoform 1
Alternative UPACC:
P14854; B2R5C9; Q6IBL4
Background:
Cytochrome c oxidase subunit 6B1, also known as Cytochrome c oxidase subunit VIb isoform 1, plays a pivotal role in the mitochondrial electron transport chain. It is a crucial component of cytochrome c oxidase, the enzyme responsible for the reduction of oxygen to water, facilitating oxidative phosphorylation. This process is vital for the production of ATP, the energy currency of the cell.
Therapeutic significance:
The protein is linked to Mitochondrial complex IV deficiency, nuclear type 7, a disorder characterized by encephalomyopathy, muscle weakness, and neurodegeneration, among other symptoms. Understanding the role of Cytochrome c oxidase subunit 6B1 could open doors to potential therapeutic strategies for this mitochondrial disorder.